Outsmarting immune suppression through GPCR innovation
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
List view / Grid view
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
Researchers at the National University of Singapore have discovered that physically squeezing stem cells through narrow spaces can trigger their transformation into bone-forming cells – potentially allowing for development of new bone repair therapies.
A new preclinical study has combined two experimental drugs that effectively block ovarian tumour growth – a strategy that could lead to new treatments against this genetically complex cancer.
Next-generation sequencing (NGS) is advancing fast – and it’s not happening in isolation. Strategic partnerships and automation are streamlining workflows and reshaping what's possible in genomics research.
Researchers at SR-TIGET in Milan have developed a novel gene therapy approach that supercharges CAR-T cell therapy against glioblastoma – strengthening treatment against one of the world’s deadliest brain cancers.
Researchers at Cold Spring Harbor Laboratory have demonstrated that an obscure RNA molecule, LINC01235, plays a crucial role in the progression of aggressive triple-negative breast cancer (TNBC) – potentially allowing for the development of targeted therapies against it.
Scientists have developed a new AI-guided tool that predicts how bowel cancer becomes resistant to treatment – which could lead to development of new personalised therapies.
Researchers have developed a new method to generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA to T cells - offering a safer, faster and more accessible alternative to traditional cell therapies for cancer and autoimmune diseases.
Amelie Croset of Molecular Partners breaks down the DARPin developments featured at AACR 2025 – from targeted radiopharmaceuticals to precision-engineered immune cell engagers.
Dr Justin Taylor of Sylvester Comprehensive Cancer Center has identified a promising drug combination that shrinks colorectal tumours in preclinical models.
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.
Researchers at Southern Medical University have developed a self-propelled ferroptosis nanoinducer that penetrates deeper into tumour tissues - offering a new strategy for safer and more effective cancer treatment.
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is leading a shift in perspective, advocating for a payload-first approach through the company’s new platform, NewPath ADC. In this interview, he…